Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG: PCI-32765

Sponsor

Dana-Farber Cancer Institute